

SOPHIRIS BIO INC.  
Form 8-K  
May 15, 2017

---

---

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**May 15, 2017**

Date of Report (Date of earliest event reported)

**Sophiris  
Bio Inc.**  
(Exact  
name of





**Item 2.02 Results of Operations and Financial Condition.**

On May 15, 2017, Sophiris Bio Inc. issued a press release announcing its financial results for the three months ended March 31, 2017. A copy of this press release is furnished herewith as Exhibit 99.1. Pursuant to the rule and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

99.1 Press release dated May 15, 2017.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Sophiris Bio Inc.**

Dated: May 15, 2017

By: /s/ Peter Slover  
Peter Slover  
Chief Financial Officer